HRP20160285T1 - Predlijek adrenomedulina na bazi polietilen glikola i njegova uporaba - Google Patents
Predlijek adrenomedulina na bazi polietilen glikola i njegova uporaba Download PDFInfo
- Publication number
- HRP20160285T1 HRP20160285T1 HRP20160285TT HRP20160285T HRP20160285T1 HR P20160285 T1 HRP20160285 T1 HR P20160285T1 HR P20160285T T HRP20160285T T HR P20160285TT HR P20160285 T HRP20160285 T HR P20160285T HR P20160285 T1 HRP20160285 T1 HR P20160285T1
- Authority
- HR
- Croatia
- Prior art keywords
- acute
- compound according
- compound
- disease
- prevention
- Prior art date
Links
- 102000004379 Adrenomedullin Human genes 0.000 title 1
- 101800004616 Adrenomedullin Proteins 0.000 title 1
- 239000002202 Polyethylene glycol Substances 0.000 title 1
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 title 1
- 229920001223 polyethylene glycol Polymers 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 13
- 230000001154 acute effect Effects 0.000 claims 7
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 6
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 230000001684 chronic effect Effects 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 206010037423 Pulmonary oedema Diseases 0.000 claims 3
- 230000002497 edematous effect Effects 0.000 claims 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 239000002245 particle Substances 0.000 claims 3
- 208000005333 pulmonary edema Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 2
- 208000010285 Ventilator-Induced Lung Injury Diseases 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- 230000006806 disease prevention Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 206010001889 Alveolitis Diseases 0.000 claims 1
- 206010002199 Anaphylactic shock Diseases 0.000 claims 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 claims 1
- 208000004990 Cardiorenal syndrome Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000004852 Lung Injury Diseases 0.000 claims 1
- 206010025282 Lymphoedema Diseases 0.000 claims 1
- 201000005085 Meconium Aspiration Syndrome Diseases 0.000 claims 1
- 206010059033 Neonatal aspiration Diseases 0.000 claims 1
- 206010035669 Pneumonia aspiration Diseases 0.000 claims 1
- 206010035742 Pneumonitis Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000021063 Respiratory fume inhalation disease Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 206010069363 Traumatic lung injury Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 208000008445 altitude sickness Diseases 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 208000021328 arterial occlusion Diseases 0.000 claims 1
- 201000009807 aspiration pneumonia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000000428 dust Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 231100000515 lung injury Toxicity 0.000 claims 1
- 208000002502 lymphedema Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000001272 neurogenic effect Effects 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 241001446247 uncultured actinomycete Species 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Dispersion Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
Claims (12)
1. Spoj s formulom
[image]
naznačen time da
n predstavlja broj 0, 1, 2 ili 3,
R1 predstavlja vodik, metil, etil, n-propil ili izopropil,
R2 predstavlja ravni ili razgranati PEG 20 kDa do 80 kDa koji kao završnu skupinu ima metoksi-skupinu,
ili jedna od njegovih soli, njegovih solvata ili solvata njegovih soli.
2. Spoj prema zahtjevu 1, naznačen time da
n predstavlja broj 1 ili 2,
R1 predstavlja vodik ili metil,
R2 predstavlja ravni PEG 40 kDa koji kao završnu skupinu ima metoksi-skupinu.
3. Spoj prema bilo kojem od zahtjeva 1 i 2, naznačen time da
n predstavlja broj 1 ili 2,
R1 predstavlja vodik,
R2 predstavlja ravni PEG 40 kDa koji kao završnu skupinu ima metoksi-skupinu.
4. Postupak za pripravu spoja s formulom (I) ili jedna od njegovih soli, njegovih solvata ili solvata njegovih soli prema zahtjevu 1, naznačen time da spoj s formulom (II)
[image]
naznačen time da
n i R1 su svaki kako je definirano u zahtjevu 1,
reagira sa spojem s formulom (III)
[image]
u kojoj
R2 je kako je definirano u zahtjevu 1.
5. Spoj prema bilo kojem od zahtjeva 1 do 3 naznačen time da je za liječenje i/ili sprječavanje bolesti.
6. Uporaba spoja prema bilo kojem od zahtjeva 1 do 3 naznačen time da je za proizvodnju lijeka za liječenje i/ili sprječavanje bolesti.
7. Uporaba spoja prema bilo kojem od zahtjeva 1 do 3 naznačen time da je za proizvodnju lijeka za liječenje i/ili sprječavanje kardiovaskularnih, edematoznih i/ili upalnih poremećaja.
8. Lijek koji sadrži spoj prema bilo kojem od zahtjeva 1 do 3 naznačen time da je u kombinaciji s inertnim netoksičnim farmaceutski prihvatljivim pomoćnim sredstvom.
9. Lijek koji sadrži spoj prema bilo kojem od zahtjeva 1 do 3 naznačen time da je u kombinaciji s dodatnom aktivnom tvari.
10. Lijek prema zahtjevu 8 ili 9 naznačen time da je za liječenje i/ili sprječavanje kardiovaskularnih, edematoznih i/ili upalnih poremećaja.
11. Uporaba spoja prema bilo kojem od zahtjeva 1 do 3 naznačen time da je za proizvodnju lijeka za liječenje i/ili sprječavanje zatajenja srca, koronarne srčane bolesti, ishemijskog i/ili hemoragijskog moždanog udara, hipertenzije, plućne hipertenzije, bolesti začepljenja perifernih arterija, preeklampsije, kronične opstruktivne plućne bolesti, astme, akutnog i/ili kroničnog plućnog edema, alergijskog alveolitisa i/ili pneumonitisa zbog udahnute organske prašine i čestica gljivica, čestica aktinomiceta ili čestica drugog podrijetla, i/ili akutnog kemijskog bronhitisa, akutnog i/ili kroničnog kemijskog plućnog edema, neurogenog plućnog edema, akutnih i/ili kroničnih plućnih manifestacija zbog zračenja, akutne i/ili kronične intersticijske plućne bolesti, akutnog oštećenja pluća/akutnog respiratornog distres sindroma (ALI/ARDS) kod odraslih ili djece uključujući novorođenčad, sekundarnog ALI/ARDS uz upalu pluća i sepsu, aspiracijske upale pluća i sekundarnog ALI/ARDS zbog aspiracije, sekundarnog ALI/ARDS zbog udisanja dimnih plinova, akutnog oštećenja pluća uzrokovanog transfuzijom (TRALI), ALI/ARDS i/ili akutne plućne insuficijencije nakon operativnih zahvata, trauma i/ili opekotina, i/ili ozljede pluća izazvane ventilatorom (VILI), ozljede pluća poslije aspiracije mekonija, plućne fibroze, visinske bolesti, kroničnih bolesti bubrega, glomerulonefritisa, akutnog oštećenja bubrega, kardiorenalnog sindroma, limfedema, upalne bolesti crijeva, sepse, septičkog šoka, sindroma sistemskog upalnog odgovora (SIRS) ne-infektivnog porijekla, anafilaktičkog šoka, upalne bolesti crijeva i/ili urtikarije.
12. Spoj kako je definiran u bilo kojem od zahtjeva 1 do 3 naznačen time da je za uporabu u postupku liječenja i/ili sprječavanja kardiovaskularnih, edematoznih i/ili upalnih poremećaja.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11187735 | 2011-11-03 | ||
PCT/EP2012/071507 WO2013064508A1 (en) | 2011-11-03 | 2012-10-30 | Polyethylene glycol based prodrug of adrenomedullin and use thereof |
EP12783566.8A EP2773376B1 (en) | 2011-11-03 | 2012-10-30 | Polyethylene glycol based prodrug of adrenomedullin and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20160285T1 true HRP20160285T1 (hr) | 2016-04-22 |
Family
ID=47146369
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20160285TT HRP20160285T1 (hr) | 2011-11-03 | 2016-03-21 | Predlijek adrenomedulina na bazi polietilen glikola i njegova uporaba |
HRP20180319TT HRP20180319T1 (hr) | 2011-11-03 | 2018-02-21 | Predlijek adrenomedulina baziran na polietilen glikolu i njegova uporaba |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20180319TT HRP20180319T1 (hr) | 2011-11-03 | 2018-02-21 | Predlijek adrenomedulina baziran na polietilen glikolu i njegova uporaba |
Country Status (45)
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6051223B2 (ja) * | 2011-11-03 | 2016-12-27 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | ペプチドの放出可能な結合のためのチロシンに基づくリンカー |
EP2896400A1 (en) * | 2014-01-17 | 2015-07-22 | Université Catholique De Louvain | Method for increasing the bioavailability of inhaled compounds |
JP6685046B2 (ja) * | 2014-03-20 | 2020-04-22 | 国立大学法人 宮崎大学 | 長時間作用型アドレノメデュリン誘導体 |
AU2015323769A1 (en) | 2014-09-26 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Stabilized adrenomedullin derivatives and use thereof |
CA2997131C (en) * | 2015-09-18 | 2021-05-25 | University Of Miyazaki | Long-acting adrenomedullin derivative |
WO2018181638A1 (ja) | 2017-03-29 | 2018-10-04 | 国立大学法人宮崎大学 | 長時間作用型アドレノメデュリン誘導体 |
GB201707938D0 (en) * | 2017-05-17 | 2017-06-28 | Univ Sheffield | Compounds |
CN114174326A (zh) | 2019-06-18 | 2022-03-11 | 拜耳公司 | 长期稳定的肾上腺髓质素类似物及其用途 |
JP7498882B2 (ja) * | 2019-12-05 | 2024-06-13 | 国立大学法人 宮崎大学 | 異常タンパク質蓄積性神経変性疾患の治療剤 |
AU2021249447A1 (en) * | 2020-04-03 | 2022-11-03 | Bayer Aktiengesellschaft | Liquid pharmaceutical formulations polyethylene glycol-based prodrugs of adrenomedullin and use |
CN115666654A (zh) | 2020-04-03 | 2023-01-31 | 拜耳公司 | 药物制剂聚乙二醇基肾上腺髓质素前药和用途 |
EP4211171A2 (en) | 2020-09-10 | 2023-07-19 | Precirix N.V. | Antibody fragment against fap |
CN112457218B (zh) * | 2020-11-05 | 2022-08-09 | 宁夏医科大学 | 2,4-二氨基丁酸衍生物的合成方法 |
AU2022330343A1 (en) | 2021-08-20 | 2024-02-08 | Bayer Aktiengesellschaft | Process for the preparation of pegylated adrenomedullin, its intermediates and use thereof |
WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5020040A (en) * | 1987-06-24 | 1991-05-28 | Digital Equipment Corporation | Overwriting system for magneto-optical recording with self timing track |
US4812590A (en) | 1987-06-25 | 1989-03-14 | Merck & Co., Inc. | Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma |
US6090800A (en) | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
CA2292902C (en) | 1999-12-24 | 2012-12-18 | Alain Cadieux | Use of calcitonin gene-related peptide in the prevention and alleviation of asthma and related bronchospastic pulmonary diseases |
EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
WO2004019993A1 (en) | 2002-08-30 | 2004-03-11 | Ramot At Tel Aviv University Ltd. | Self-immolative dendrimers releasing many active moieties upon a single activating event |
US7705045B2 (en) | 2002-11-14 | 2010-04-27 | Syntarga, B.V. | Prodrugs built as multiple self-elimination-release spacers |
EP1646813B1 (en) | 2003-07-23 | 2013-06-12 | PPG Industries Ohio, Inc. | Composite seal and window assembly |
AU2005232371B2 (en) | 2004-03-23 | 2010-10-14 | Complex Biosystems Gmbh | Polymeric prodrug with a self-immolative linker |
EP1749026B1 (en) | 2004-05-24 | 2011-11-23 | Institut de Cardiologie de Montréal | Labelled adrenomedullin derivatives and their use for imaging and therapy |
GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
US8273325B2 (en) * | 2006-12-20 | 2012-09-25 | Ge Healthcare As | Contrast agents |
WO2008138141A1 (en) | 2007-05-11 | 2008-11-20 | Institut De Cardiologie De Montréal | Labelled adrenomedullin derivatives and their use for imaging and therapy. |
EP2525831B1 (en) | 2010-01-22 | 2019-05-15 | Ascendis Pharma A/S | Carrier-linked carbamate prodrug linkers |
JP6051223B2 (ja) * | 2011-11-03 | 2016-12-27 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | ペプチドの放出可能な結合のためのチロシンに基づくリンカー |
-
2011
- 2011-11-03 JO JOP/2019/0001A patent/JOP20190001B1/ar active
-
2012
- 2012-10-24 JO JOP/2012/0324A patent/JO3385B1/ar active
- 2012-10-29 UY UY0001034419A patent/UY34419A/es unknown
- 2012-10-29 UY UY0001037922A patent/UY37922A/es active IP Right Grant
- 2012-10-30 KR KR1020187027464A patent/KR102004668B1/ko active IP Right Grant
- 2012-10-30 HU HUE15192265A patent/HUE036535T2/hu unknown
- 2012-10-30 CA CA2854134A patent/CA2854134C/en active Active
- 2012-10-30 ME MEP-2016-56A patent/ME02379B/me unknown
- 2012-10-30 DK DK15192265.5T patent/DK3075395T3/en active
- 2012-10-30 NO NO15192265A patent/NO3075395T3/no unknown
- 2012-10-30 EP EP12783566.8A patent/EP2773376B1/en active Active
- 2012-10-30 PL PL12783566T patent/PL2773376T3/pl unknown
- 2012-10-30 CN CN201610837728.9A patent/CN107412740B/zh active Active
- 2012-10-30 TR TR2018/02124T patent/TR201802124T4/tr unknown
- 2012-10-30 SI SI201230498A patent/SI2773376T1/sl unknown
- 2012-10-30 PE PE2014000540A patent/PE20141219A1/es active IP Right Grant
- 2012-10-30 IN IN3290CHN2014 patent/IN2014CN03290A/en unknown
- 2012-10-30 EP EP15192265.5A patent/EP3075395B1/en active Active
- 2012-10-30 KR KR1020147013845A patent/KR101965467B1/ko active IP Right Grant
- 2012-10-30 SG SG11201400924TA patent/SG11201400924TA/en unknown
- 2012-10-30 EA EA201600495A patent/EA029410B1/ru not_active IP Right Cessation
- 2012-10-30 UA UAA201405818A patent/UA111098C2/uk unknown
- 2012-10-30 ES ES15192265.5T patent/ES2659195T3/es active Active
- 2012-10-30 MY MYPI2014701087A patent/MY173372A/en unknown
- 2012-10-30 DK DK12783566.8T patent/DK2773376T3/en active
- 2012-10-30 AR ARP120104059A patent/AR088582A1/es active Pending
- 2012-10-30 MX MX2017011334A patent/MX361287B/es unknown
- 2012-10-30 CN CN201280053588.6A patent/CN103998063B/zh active Active
- 2012-10-30 SG SG10201607516SA patent/SG10201607516SA/en unknown
- 2012-10-30 RS RS20160172A patent/RS54623B1/en unknown
- 2012-10-30 WO PCT/EP2012/071507 patent/WO2013064508A1/en active Application Filing
- 2012-10-30 LT LTEP15192265.5T patent/LT3075395T/lt unknown
- 2012-10-30 ES ES12783566.8T patent/ES2568063T3/es active Active
- 2012-10-30 MY MYPI2018001427A patent/MY194197A/en unknown
- 2012-10-30 PL PL15192265T patent/PL3075395T3/pl unknown
- 2012-10-30 EA EA201400528A patent/EA025631B1/ru not_active IP Right Cessation
- 2012-10-30 SI SI201231218T patent/SI3075395T1/en unknown
- 2012-10-30 MX MX2014004384A patent/MX350341B/es active IP Right Grant
- 2012-10-30 HU HUE12783566A patent/HUE027333T2/en unknown
- 2012-10-30 JP JP2014539315A patent/JP5995984B2/ja active Active
- 2012-10-30 RS RS20180141A patent/RS56819B1/sr unknown
- 2012-10-30 PT PT151922655T patent/PT3075395T/pt unknown
- 2012-10-30 BR BR112014010708-4A patent/BR112014010708B1/pt active IP Right Grant
- 2012-10-30 PE PE2018001536A patent/PE20181493A1/es unknown
- 2012-10-30 US US14/355,568 patent/US9603936B2/en active Active
- 2012-10-30 AU AU2012331244A patent/AU2012331244B2/en active Active
- 2012-11-02 TW TW101140660A patent/TWI583396B/zh active
- 2012-11-02 TW TW106104340A patent/TWI653051B/zh active
-
2014
- 2014-04-09 IL IL232037A patent/IL232037B/en active IP Right Grant
- 2014-04-10 CO CO14078051A patent/CO7020863A2/es unknown
- 2014-04-14 CL CL2014000948A patent/CL2014000948A1/es unknown
- 2014-04-15 DO DO2014000078A patent/DOP2014000078A/es unknown
- 2014-04-23 CR CR20140184A patent/CR20140184A/es unknown
- 2014-04-28 EC ECSP14013326 patent/ECSP14013326A/es unknown
- 2014-04-28 MA MA36961A patent/MA35618B1/fr unknown
- 2014-04-29 CU CUP2014000051A patent/CU24184B1/es active IP Right Grant
- 2014-04-30 GT GT201400085A patent/GT201400085A/es unknown
- 2014-04-30 TN TNP2014000185A patent/TN2014000185A1/en unknown
-
2015
- 2015-12-31 US US14/986,488 patent/US9649363B2/en active Active
-
2016
- 2016-01-20 ZA ZA2016/00434A patent/ZA201600434B/en unknown
- 2016-03-21 HR HRP20160285TT patent/HRP20160285T1/hr unknown
- 2016-04-12 CY CY20161100293T patent/CY1117354T1/el unknown
- 2016-08-23 JP JP2016162327A patent/JP6177975B2/ja active Active
-
2017
- 2017-03-29 US US15/472,476 patent/US10035818B2/en active Active
- 2017-05-15 IL IL252281A patent/IL252281B/en active IP Right Grant
- 2017-05-22 AU AU2017203423A patent/AU2017203423B2/en not_active Ceased
-
2018
- 2018-02-07 CY CY20181100151T patent/CY1119897T1/el unknown
- 2018-02-21 HR HRP20180319TT patent/HRP20180319T1/hr unknown
- 2018-03-19 IL IL258229A patent/IL258229B/en active IP Right Grant
- 2018-04-25 HK HK18105356.7A patent/HK1246147A1/zh unknown
- 2018-09-20 EC ECSENADI201871104A patent/ECSP18071104A/es unknown
- 2018-09-20 DO DO2018000203A patent/DOP2018000203A/es unknown
- 2018-11-05 AR ARP180103212A patent/AR113830A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20160285T1 (hr) | Predlijek adrenomedulina na bazi polietilen glikola i njegova uporaba | |
PH12019501098A1 (en) | Pyrrolopyrimidines as cftr potentiators | |
ES2368967T3 (es) | Combinaciones de benzotiazol agonista del adrenorreceptor beta 2. | |
HRP20200429T1 (hr) | 3,5-diamino-6-kloro-n-(n-(4-(4-(2-(heksil(2,3,4,5,6-penta-hidroksiheksil)amino)etoksi)fenil)butil)karbamimidoil)pirazin-2-karboksamid | |
HRP20171044T1 (hr) | Kemijski i metabolički stabilni dipeptid s potentnom aktivnošću blokatora natrijevog kanala | |
JP2012503668A5 (hr) | ||
HRP20100359T1 (hr) | Specifični glukokortikoidni spoj s protuupalnom aktivnošću | |
JP2018505192A5 (hr) | ||
EA201270561A1 (ru) | Антагонисты рецептора cgrp | |
JP2012025755A5 (hr) | ||
HRP20120708T1 (hr) | Kombinacija antikolinergika, glukokortikoida i beta2-agonista za lijeäśenje upalnih bolesti | |
JP2015517489A5 (hr) | ||
RU2015144083A (ru) | Комбинация лекарственных средств | |
CO6640319A2 (es) | Formulación en polvo seca que comprende una droga antimuscarínica | |
CL2009000198A1 (es) | Compuestos derivados del acido {2'-[(amino n,n-disustituido)-metil]-bifenil-3-il} acetico, mediadores de prostaglandina d2; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad respiratoria, alergica o inflamatoria, tal como el asma, epoc o rinitis alergica. | |
WO2011141929A3 (en) | Aqueous pharmaceutical compositions of fluticasone and olopatadine | |
RU2019121673A (ru) | Активаторы nrf2 | |
EA201590019A1 (ru) | Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы | |
JP2020516689A5 (hr) | ||
JP2012509922A5 (hr) | ||
JP2009532413A5 (hr) | ||
JP2014520854A5 (hr) | ||
EA201201393A1 (ru) | Ингалятор, разработанный для доставки лекарственного средства в виде сухого порошка | |
JP2018520986A5 (hr) | ||
SG188575A1 (en) | Novel combinations |